Jon Ellis
Director/Board Member en Orchard Therapeutics (Europe) Ltd. .
Perfil
En la actualidad, Jon Ellis ocupa el cargo de Vicepresidente y Director de Ciencia y Tecnología en GlaxoSmithKline Plc. También forma parte del consejo de Orchard Therapeutics (Europe) Ltd. y de Orchard Therapeutics Plc. El Dr. Ellis se doctoró en la Universidad de Cambridge, obtuvo un MBA en el Henley Management College y se licenció y graduó en el Magdalene College.
Cargos activos de Jon Ellis
Empresas | Cargo | Inicio |
---|---|---|
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Director/Board Member | 02/08/2018 |
Antiguos cargos conocidos de Jon Ellis.
Empresas | Cargo | Fin |
---|---|---|
GSK PLC | Chief Tech/Sci/R&D Officer | 01/08/2022 |
ORCHARD THERAPEUTICS PLC | Director/Board Member | 16/06/2021 |
Formación de Jon Ellis.
University of Cambridge | Doctorate Degree |
Henley Management College | Masters Business Admin |
Magdalene College | Graduate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
GSK PLC | Health Technology |
Empresas privadas | 2 |
---|---|
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Orchard Therapeutics Plc
Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Jon Ellis